SCHEMBL24627701

SCHEMBL24627701

CCCCCCCCC(CCCCCCCC)OC(=O)CCN(CCC(=O)OC(CCCCCCCC)CCCCCCCC)CCN1CCN(C)CC1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 2/20 0.41
MAPK1 P28482 2/20 0.41
THRA P10827 1/20 0.40
THRB P10828 1/20 0.40
LMNA P02545 4/20 0.40
ALDH1A1 P00352 1/20 0.40
PAOX Q6QHF9 1/20 0.38
PRKCA P17252 1/20 0.37
PRKCE Q02156 1/20 0.37
PRKCQ Q04759 1/20 0.37
PRKCD Q05655 1/20 0.37
GAA P10253 1/20 0.37
TLR2 O60603 1/20 0.36
USP2 O75604 1/20 0.35
MEN1 O00255 1/20 0.35
GMNN O75496 1/20 0.35
HSP90AA1 P07900 1/20 0.35
BLM P54132 1/20 0.35
KMT2A Q03164 1/20 0.35
NPSR1 Q6W5P4 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31663675 0.95 MAPK1 (0.43) MAPTMAPK1LMNAALDH1A1PRKCA
SCHEMBL24628009 0.93 PAOX (0.43) MAPTMAPK1THRATHRBLMNA
SCHEMBL30966075 0.93 PAOX (0.43) MAPTMAPK1THRATHRBLMNA
SCHEMBL24627622 0.93 PAOX (0.43) MAPTMAPK1THRATHRBLMNA
SCHEMBL24627850 0.91 GAA (0.45) MAPTMAPK1THRATHRBLMNA
SCHEMBL24627591 0.90 FAAH (0.49) MAPTALDH1A1PRKCAPRKCEPRKCQ
SCHEMBL31663671 0.90 MAPK1 (0.46) MAPTMAPK1LMNAALDH1A1PRKCA
SCHEMBL25530864 0.90 MAPK1 (0.48) MAPTMAPK1LMNAALDH1A1PRKCA
SCHEMBL24628004 0.90 GAA (0.47) MAPTMAPK1THRATHRBLMNA
SCHEMBL24627804 0.88 MAPK1 (0.44) MAPTMAPK1THRATHRBLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2026047603-A1 SARS-COV-2 IMMUNOGENIC COMPOSITIONS BioNTech SE (DE) 2026-03-05 WO disclosed
EP-4683642-A1 STABILIZED NUCLEIC ACID COMPOSITIONS AND METHODS FOR PREPARING, STORING AND USING THE SAME BioNTech SE (DE) 2026-01-28 EP disclosed
EP-4658248-A1 COMPOSITIONS AND METHODS BioNTech SE (DE) 2025-12-10 EP disclosed
WO-2025149492-A1 RNA ENCODING AN IMMUNE INHIBITORY IL-1 FAMILY MEMBER BioNTech SE (DE) 2025-07-17 WO disclosed
WO-2025106738-A1 SARS-COV-2 IMMUNOGENIC COMPOSITIONS BioNTech SE (DE) 2025-05-22 WO disclosed
WO-2025106754-A1 CORONAVIRUS VACCINE BioNTech SE (DE) 2025-05-22 WO disclosed
WO-2024194454-A1 STABILIZED NUCLEIC ACID COMPOSITIONS AND METHODS FOR PREPARING, STORING AND USING THE SAME BioNTech SE (DE) 2024-09-26 WO disclosed
WO-2024160826-A1 COMPOSITIONS AND METHODS BioNTech SE (DE) 2024-08-08 WO disclosed
US-20220218622-A1 IONIZABLE LIPIDS AND METHODS OF MANUFACTURE AND USE THEREOF THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA 2022-07-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220218622-A1 IONIZABLE LIPIDS AND METHODS OF MANUFACTURE AND USE THEREOF NPC1L1, PLA2G4A, PLA2G2A MAPT 2748/4885MAPK1 4647/4885THRA 1886/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.